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COVID-19 is described in a clinical case involving a patient who proposed the hypothesis that
Nuclear factor (erythroid-derived 2)-like 2 (Nrf2)-interacting nutrients may help to prevent severe
COVID-19 symptoms. Capsules of broccoli seeds containing glucoraphanin were being taken
before the onset of SARS-CoV-2 infection and were continued daily for over a month after the first
COVID-19 symptoms. They were found to reduce many of the symptoms rapidly and for a duration
of 6–12 h by repeated dosing.When the patient was stable but still suffering from cough and nasal
obstruction when not taking the broccoli capsules, a double-blind induced cough challenge
confirmed the speed of onset of the capsules (less than 10 min). A second clinical case with lower
broccoli doses carried out during the cytokine storm confirmed the clinical benefits already
observed. A third clinical case showed similar effects at the onset of symptoms. In the first clinical
trial, we used a dose of under 600 mmol per day of glucoraphanin. However, such a high dose may
induce pharmacologic effects that require careful examination before the performance of any
study. It is likely that the fast onset of action is mediated through the TRPA1 channel. These
experimental clinical cases represent a proof-of-concept confirming the hypothesis that Nrf2-
interacting nutrients are effective in COVID-19. However, this cannot be used in practice before
the availability of further safety data, and confirmation is necessary through proper trials on effi-
cacy and safety.
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The present report consists of the self-
description of a COVID-19 case where the pa-
tient – who is also the author — describes his clinical
course as well as the anecdotal evidence of
symptom improvement after treatment with broc-
coli capsules. Since the patient himself developed
the concept that Nrf2-interacting nutrients may
help to prevent severe COVID-19 symptoms or,
less likely, to prevent SARS-CoV-2 infection,1–3 he
took low-dose broccoli capsules with glucor-
aphanin and myrosinase to prevent the infection,
and higher doses when COVID-19 was clinically
evident. Broccoli was chosen as it contains glu-
coraphanin that is obtained from cruciferous veg-
etables such as broccoli, Brussels sprouts, and
cabbage. The most potent Nrf2 natural activator is
sulforaphane,4–10 but it is difficult to deliver in an
enriched and stable form for purposes of direct
human consumption.11 Thus, glucoraphanin, the
precursor of sulforaphane, is administered orally
with myrosinase, the enzyme that transforms
glucoraphanin into sulforaphane.
After the cytokine storm, the patient continued
to suffer from cough and nasal obstruction when
he was not taking the broccoli capsules. A double-
blind induced cough challenge was carried out to
assess the speed of onset of the broccoli capsules.Hypothesis: the heterogeneity of COVID-19 death
rates between countries could be partially due to
the consumption of Nrf2-interacting nutrients
There are large between- and within-country
variations in COVID-19 death rates. Some very
low death rate settings — such as those of Eastern
Asia, Central Europe, the Balkans and Africa — have
a common feature of eating large quantities of
fermented foods and some specific vegetables
such as cabbage. Although biases exist when
examining ecological studies, fermented vegeta-
bles and cabbage can be associated with lower
death rates in European countries. Many foods
have antioxidant properties and many mechanisms
may be involved. However, the activation of the
Nrf2 (Nuclear factor (erythroid-derived 2)-like 2)
anti-oxidant transcription factor may be of primary
importance. Nrf2 is the main regulator of the
antioxidant response in humans. It modulates the
expression of hundreds of genes, including notonly the antioxidant enzymes (ie, glutathione
related), but also the large number of genes that
control seemingly disparate physiopathological
processes.12,13 Nrf2 activity can block the
Angiotensin II receptor type 1 (AT1R) axis as well
as endoplasmic reticulum stress.
Cabbage contains precursors of sulforaphane,
the most active natural activator of Nrf2. Fer-
mented vegetables contain many lactobacilli,
which are also potent Nrf2 activators. Three ex-
amples where the association with COVID-19
mortality could have been influenced by the
presence or lack of fermented vegetable con-
sumption were proposed: Kimchi in Korea, west-
ernized foods, and the slum paradox. It was
expected that the COVID-19 pandemic would be
catastrophic in the slum areas of middle- or low-
income countries due to inequalities in the work-
force of essential services, poverty, access to care,
or air pollution.14,15 In Mumbai, although a large
number of people living in slums are infected by
COVID-19, the death rate is very low.16 It is
possible that eating fermented foods and spices
may prevent against severe COVID-19. Kimchi is
a traditional Korean fermented food usually con-
taining cabbage and/or radish (Nrf2),3,17 garlic,
red pepper, ginger, and other spices (TRPA1/
TRPV1).17 Fermentation by lactic acid bacilli
increases the health benefits of Kimchi (Nrf2). It is
proposed that Kimchi and other fermented
vegetables and spices largely eaten in Asia may
partly explain the low prevalence of severe
COVID-19 in these countries.3
There are many Nrf2-interacting nutrients
(berberine, curcumin, epigallocatechin gallate,
genistein, quercetin, resveratrol, sulforaphane,
and many others) that all act similarly to reduce
insulin resistance, endothelial damage, lung
injury, and cytokine storm (Bousquet et al, sub-
mitted). They also act on the same mechanisms
(mTOR: Mammalian target of rapamycin, PPARg:
Peroxisome proliferator-activated receptor,
NFkB: Nuclear factor kappa B, ERK: Extracellular
signal-regulated kinases and eIF2a: Elongation
initiation factor 2a). As a result, they may be
important in mitigating the severity of COVID-19,
acting through the endoplasmic reticulum stress
or ACE-Angiotensin–II–AT1R axis (AT1R) pathway.
Interestingly, geographical areas with very low
COVID-19 mortality are those with the lowest
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Asia).
We proposed that Nrf2-interacting foods and
nutrients can re-balance insulin resistance and
have a significant effect on COVID-19 severity. It is
possible, therefore, that the intake of these foods
may restore an optimal natural balance for the Nrf2
pathway and be of interest in the mitigation of
COVID-19 severity. Understanding the balance
between Nrf2-interacting foods and nutrients
would help to: (i) better understand the mecha-
nisms of the oxidative stress in insulin resistance-
associated diseases, (ii) develop optimal Nrf2-
interacting nutrients and diets to reduce the
prevalence and severity of IR diseases, (iii) opti-
mize Nrf2 drug development, and (iv) develop
these strategies to mitigate COVID-19 severity.
Fast onset of broccoli capsules with glucoraphanin
on COVID-19 symptoms
Clinical case 1
The hypothesis that an oral administration of
broccoli seeds and glucoraphanin capsules (from
now on broccoli capsules) could beneficially
ameliorate the COVID-19 course was tested on a
73-year old man, a former professor of respiratory
medicine at the Montpellier University of France
(BMI 23, allergic rhinitis, intermittent untreated
asthma, and well-controlled type-2 diabetes underFig. 1 Clinical case. Only The highest daily score of symptoms for the
symptoms. Fatigue VAS: 0: none, 10: extrememetformin, HbA1C: 6.2%). Before developing
COVID-19, the patient self-prescribed broccoli
capsules OD in the morning for 45 days (Aero-
biane, Pileje, France: broccoli seeds
300 mg þ glucoraphanin 30 mg, and myrosinase)
in the hope to prevent the onset of COVID-19. But
he did contract the infection. After mass spec-
trometry analysis, it was found that the dose of
glucoraphanin was 9 mg, around 25 mmol.
Day 1: He started to experience COVID-19
symptoms on August 22, 2020 (Fig. 1). A few
months ago, the patient developed a COVID-19
app (MASK-COVID) — available on Android — us-
ing the estimation of symptom severity by visual
analogue scale (VAS) based on his previous
experience of developing an allergy app.18 He
used VAS to score his daily symptoms on paper,
as the app is not yet available on iOS and the
patient did not have access to Android. For each
day, the maximal VAS was reported. For days 1
to 3, VAS was estimated retrospectively.
Days 2–4: The symptoms began with mild
cough (VAS: 2/10), followed 12 h later by severe
fatigue (VAS: 6/10) and then, at 24 h, fever (38.9).
At 36 h, he also experienced loss of appetite (VAS:
7/10), nausea (VAS: 3/10), diarrhea (VAS: 2/10),
hyposmia (VAS: 3/10), dysgeusia (VAS: 3/10), and
nasal obstruction (VAS: 4/10) (Fig. 1).day are shown. “Days” indicate the number of days since the first
Fig. 2 Evolution of symptoms after ingestion of broccoli capsules. VAS: 0: none, 10 extreme
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coli capsules on day 3. The first dose of 600 mg of
broccoli (4 capsules) (7:00) improved the symp-
toms incompletely, and he therefore took a higher
dose 5 h later (900 mg). Interestingly, the ingestion
of the capsules always induced the same effect
with rapid disappearance of cough, nasal
obstruction, nausea and diarrhea, improvement in
fatigue, and some reduction in fever (Fig. 2). He
repeated this dose when nasal obstruction
reappeared and cough increased in severity
(VAS>5/10), needing capsules every 6–8 h
(12:00, 18:00, 23:00, 7:00, 13:00) to achieve
symptom control (Fig. 2). At 14:30 on day 4, the
patient felt well, had no fever, and was
asymptomatic.
Since the patient found the symptoms bother-
some on day 3, he contacted Prof. H. Blain (HB:
geriatrician, Montpellier) — with whom he is work-
ing on COVID-19 in home care services19 — and
discussed the Nrf2 hypothesis.2,3 HB considered
that the initial symptoms were severe and
contacted (day 4) Prof. V. Le Moing (VLM:
Director of the COVID-19 clinic of the Montpellier
hospital). Then, for the next 3 weeks, the patient
had daily contact with VLM by phone or SMS to
adjust the treatment. Hospitalization would have
been proposed at the very first sign of severity of
the cytokine storm (eg, respiratory rate >24/min).
To optimize shared decision making, the patient
scored all of the symptoms on a VAS scale (0–10)
and reported them at least once daily to VLM. He
also had regular contact with Dr.W Czarlewski with
whom he developed the Nrf2 hypothesis.2,3 Dr.Czarlewski is knowledgeable on natural medicine
and was able to discuss the dosage of the
broccoli capsules.
Days 5–6: The patient took 3 broccoli capsules
(450 mg) 3 times per day and felt well.
Days 7–12 (Fig. 1): The symptoms of the
cytokine storm began on day 7, and the patient
increased the dose of broccoli (900 mg). He
noted the same rapid effect for the following 2
days (days 7 and 8) (Fig. 2) and took 1 dose
every 6 h when cough reappeared and increased
in severity (VAS>5). The total daily dose of
broccoli seeds was 2.7 g and of glucoraphanin
270 mg (around 600 mmol).
On day 8, fever did not decrease and so he
added paracetamol (3 g a day for 4 days). Fever
reduced to 36.9 (morning) and 37.3 (evening)
and remained the same up to day 13. Interestingly,
the intervals between the broccoli doses (900 mg)
could then be increased to 10–12 h. The patient's
respiratory rate was never >20/min. Since the
symptoms were controlled (including fatigue VAS:
2–4/10) and the respiratory rate was not increased,
the patient stayed at home, under the twice-daily
supervision of VLM.
Days 13–20: On day 13, the patient felt well
and had no fever. A dose of 900 mg of broccoli
BID was ingested. However, he developed a pro-
ductive cough (yellow eosinophil-like sputum).
Further to shared decision making with VLM, the
patient took Prednisone (60 mg/day) on days 14–
Fig. 3 Evolution of symptoms at days 21–22. Fatigue VAS: 0: none, 10 extreme, for appetite: loss of appetite
Volume 14, No. 1, January 2021 517 which resulted in translucent sputum. After day
22, the sputum production ceased.
Days 21–24: On day 21, the patient stopped
the broccoli capsules because he was travelling
and had forgotten them (Fig. 3). He experienced
a recurrence of symptoms with increasing fatigue,
loss of appetite, nausea and, later, within 24 h,
cough and fever. He was obliged to wait for 3h
after the onset of symptoms before taking the
capsules and had not experienced such a
severe cough since the beginning of the
infection. The patient took 600 mg of broccoli
capsules and, within 5 min, the cough had
reduced and the nausea had disappeared.
Given that his fever was still at 38.9, he tookFig. 4 Evolution of symptoms at day 251 g of paracetamol. The fever decreased to
38.1 within minutes. Since cough was not
reduced, he took another 600 mg of broccoli
capsules and it improved. After 2 h of
perspiring, the patient's temperature had fallen
to 36.9. He then felt perfectly well and
experienced no further fatigue or cough. The
next morning, the patient felt well with a return
of appetite and no fatigue. He then took
300 mg of broccoli morning and evening (days
23–24).
Day 25: The patient purposely delayed the
broccoli treatment to determine whether it was
needed, and the same symptoms returned (fa-
tigue, cough, nausea, fever) (Fig. 4). He then
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broccoli capsules. The cough became very
severe (VAS 8/10) and his temperature
increased to 38.9. He took the broccoli
capsules (1200 mg) and paracetamol, and the
same sequence of events was observed.
Days 26–38: Every day, the patient took 2
capsules (300 mg) in the morning and 2 during the
day. After ingestion of the broccoli, he was rapidly
almost symptom free (VAS 1–2 for nasal symptoms
and spontaneous cough). After 10–12 h, the cough
and nasal obstruction returned. When cough VAS
was over 5, he took the broccoli capsules. On days
30 and 31, the patient did not take the capsules
and did a double-blind, placebo-controlled
challenge.
Over the course of the disease, the patient
attempted to improve cough using formoterol-
budesonide low dose, but there was no effect.
He also attempted to control nasal obstruction
using azelastine-fluticasone propionate without
any effect.
Biological tests and CT-scan
The patient had a first positive PCR test to SARS-
CoV-2 on August 24 (day 3). The test was repeated
on September 15 and was still positive, showing
IgG antibodies to SARS-CoV-2. He had a moderate
inflammation (September 15): CRP 30 mg/l, D-di-
mers (945 ng/ml), no lymphopenia, and normal
hepatic and kidney biology.
The lung CT-scan carried out on September 18
showed that less than 25% of the lung was
impacted with patchy images.
Clinical case 2
A 61-year old woman in perfect health and
receiving no treatment developed mild COVID-19
symptoms on September 28 (nasal obstruction,
cough, fatigue, and headache) that disappeared
on day 2 (Table 1). On October 1 (day 4), she had
most of the COVID-19 symptoms including loss of
taste, smell, and appetite. On day 6, she took
300 mg of broccoli capsules at 14h30. In 10 min,
cough and nausea disappeared, and smell and
taste improved. Fever decreased over 5 h from
38.3 to 37.2. After 6 h, at 20h30, fever (38.2),
nasal obstruction and cough (VAS 5) reappeared.She took the same dose of broccoli with paracet-
amol (1000 mg) and the same improvements were
noticed for a longer period of time (13 h). The third
episode occurred the next morning. She then took
broccoli capsules (300 mg) and the same
sequence of improvement was observed for 8 h.
The fourth episode occurred at 18h45 and, after
taking broccoli (300 mg) and paracetamol
(500 mg), the duration of the effect was around
15 h. The fifth episode occurred at 10h15. She took
broccoli (300 mg), and symptoms did not re-occur
until 19h15. She then took broccoli (300 mg) and
paracetamol 500 mg and the same improvement
was experienced for 14 h. Other episodes were
less clear as she was improving. Interestingly, loss
of smell and taste were improved by the broccoli,
but the extent of this improvement may have
required specific testing for a more accurate
assessment (even though VAS is accurate).
The patient tested positive for SARS-CoV-2 on
day 8.Clinical case 3
A 63-year-old man with controlled hypertension
and receiving losartan had the first COVID-19
symptoms on October 3. He had rhinorrhea, dry
cough, incomplete loss of smell and taste, and
fatigue on day 2. On day 3 at 11h00, he had severe
cough and fever and took 300 mg of broccoli.
Cough and nasal obstruction disappeared very
rapidly but fever was slower (Table 2). He took the
same treatment with 500 mg of paracetamol (after
the third dose) five times, and cough (VAS 5–8)
always disappeared within 10 min. Nasal
obstruction showed a similar trend in case 3 (in
case 2 there were no nasal symptoms). Loss of
smell and taste (VAS 6) on the first 2 days were
improved after the first broccoli capsule (VAS 5)
and were overall largely improved (VAS 0 at the
last evaluation of day 5). Fatigue and fever
appeared to be improved by broccoli, but the
results were less consistent. Paracetamol was
given 5 times and increased the duration of the
benefit obtained with broccoli.
The patient tested positive for SARS-CoV-2 on
day 3.





4 8 38.6 6 0 10 10 0
5 8 38.5 10 5 10 10 5
6 14h30 7 38.3 5 8 10 10 0 2
14h40 0 38 3 8 5 7 0
15h00 0 37.9 0 8 5 5 0
16h00 0 37.6 0 8 5 5 0
18h00 0 37.2 0 8 5 5 0
7 20h30 5 38.2 5 8 5 5 5 2 1000 mg
20h45 0 37.9 5 8 5 5 5
08h00 0 37.2 8 5 5 5 5
10h20 7 37.8 6 8 5 5 5 2
10h40 0 37.7 3 8 3 3 0
18h45 7 37.8 5 8 5 5 5 2 500 mg
19h00 0 37.8 0 8 5 5 0
8 10h15 7 37.2 0 5 5 5 5 2
10h30 0 37.2 0 5 3 5 3
14h00 2 37.2 0 4 4 4 0
16h30 3 37.3 0 3 3 3 0
19h15 7 37.2 0 3 3 3 0 2 500 mg
19h30 0 37.2 0 3 3 3 0
21h00 0 37.2 0 3 3 3 0
9 09h00 0 37.8 5 4 8 8 8 2 500 mg
10h30 0 37.6 3 4 3 3 3
12h00 0 37.7 0 2 2 0 0
20h30 7 38 3 2 2 0 0 2 500 mg
21h00 0 37.9 3 2 2 0 0
22h00 0 37.6 3 2 2 0 0
Table 1. Clinical case 2
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The patient is allergic to grass pollen and cat,
and has moderate-to-severe allergic rhinitis which
is perfectly controlled by PRN medications. Furtherto the onset of COVID-19, he experienced mild to
moderate nasal obstruction (VAS up to 6/10) and
occasional episodes of mild rhinorrhea (up to 3/
10). The rhinorrhea did not have the features of
allergic rhinitis. The patient attempted to reduce





1 0 0 8 6 5 5 5
2 18h00 5 37.2 0 0 6 6 0
3 09h30 8 38 5 0 5 5 0
11h00 8 37.8 6 0 5 5 0 2
11h15 0 37.7 6 0 5 5 0
12h30 0 37.6 3 0 5 5 0
15h15 8 37 2 0 5 5 0
16h30 8 37.8 5 0 5 5 5
19h00 8 38.6 5 0 5 5 4 2 1000 mg
19h15 0 39.2 7 0 5 5 0
21h00 0 38.8 9 5 5 5 0
4 09h00 5 37.9 5 0 4 4 6 2 500 mg
10h30 0 37.5 5 0 0 0 0
12h00 0 37 5 0 0 0 0
21h00 0 37.9 6 5 4 4 0 2 1000 mg
21h15 0 37.7 0 5 4 4 0
22h00 0 37.4 0 5 4 4 0
5 09h15 5 37.7 5 8 4 4 6 2 1000 mg
09h30 5 38.1 5 5 4 4 0
12h00 3 37.6 3 0 3 3 0
12h30 0 37.2 0 0 0 0 0
15h30 5 37.8 0 0 0 0 3
17h00 0 38.6 7 0 0 0 3
21h00 4 37.9 3 0 0 0 3 2 1000 mg
21h15 2 37.7 3 0 0 0 3
Table 2. Clinical case 3
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onate but this was not effective. The patient did not
experience any sneezing, nasal pruritus, or eye
symptoms. He proposed a score for his symptoms
according to the VAS for allergic rhinitis (from 0 to
10).20–22 He noticed that nasal symptoms and
cough always improved within minutes of
ingesting the broccoli capsules and thenreappeared with cough when the treatment
became ineffective.
Design of the test
The patient also suffers from mild intermittent
asthma, especially when exposed to high levels of
air pollution. He uses formoterol-budesonide low
dose when needed, with a maximal annual
Spontaneous cough VAS Induced cough challenge score
5 coughs for one episode 3 persisting severe cough 9–10
2-4 coughs for one episode 2 >3 cough, intolerable 8
1 cough for one episode 1 >3 cough, severe 7
>3 cough, mild 6
2-3 cough severe 5




Table 3. Cough symptom score
Volume 14, No. 1, January 2021 9consumption of around 40 doses. He has a severe
bronchial hyperreactivity. During the COVID-19
infection, he had symptoms — that were not well
defined — in the form of an intermittent pruritus of
the tracheobronchial tree, followed, within mi-
nutes, by dry cough. He had never experienced
such symptoms. He used formoterol-budesonide
low dose to reduce cough, but this was not effec-
tive. These symptoms were always followed by a
more severe cough, and the patient ingested the
broccoli capsules when cough was over 4 or 5/10
(VAS). There are many scores for cough 23,24 and
he used a VAS score for “cough”. When he had
pruritus, a deep inspiration followed by a rapid
expiration led to immediate mild “wheezing” (not
similar to asthma) and to cough that could be
scored. He also used a score for induced cough
during challenge, with some criteria. For
spontaneous cough during challenge, he
decided to count the number of coughs per
episode (Table 4).Open label induced cough challenge with broccoli
(days 26–28 and 31–38)
In order to test the induced cough challenge
and the dose that could be effective, the patient
performed 3 induced cough challenges with a
dose of 300 mg of broccoli (daily dose recom-
mended). Similar to the FEV1, he took the deepest
breath he could, and then exhaled as fast and as
hard as possible and counted the number of
coughs (see Table 2). He found that induced
cough (by inhalation challenge) improved within10 min after broccoli ingestion, and nasal
obstruction even more rapidly. He then selected
this dose for the DB, PC challenge.
After the DB, PC challenge, when the patient
needed the broccoli capsules (VAS spontaneous
cough >5/10), he performed an open challenge at
least once a day. A total of 7 challenges were
carried out (Table 3).Double-blind induced cough challenge with
broccoli (days 29–30)
A double-blind placebo-controlled trial was car-
ried out on induced cough using 4 placebo cap-
sules or 4 broccoli (300mg) capsules.The challenge
was performed double-blind to confirm that the
effect of broccoli seed capsules was real and not
biased. The placebo and broccoli capsules were
prepared by the Pharmacie des Quatre Seigneurs
(Montpellier). The capsules were made up of cellu-
lose (opaque). Neither the broccoli nor the cellu-
lose capsules had any taste, thus there was a total
placebo effect. The investigator was not aware of
the blinding, nor of the code that was broken after
the test. Similar to the open challenge, he took the
deepest breath he could, and then exhaled as fast
and as hard as possible. He started the test when
spontaneous cough VAS was over 5/10. He first
measured spontaneous and induced cough scores
as well as nasal VAS, 5 min before ingesting the
capsule. He ingested the capsule and then
measured the 3 parameters every minute for
10 min, at 12, 15, 17, 20, 25, 30, 45 and 60 min.
Fig. 5 Double-blind placebo-controlled challenge (300 mg broccoli (BG) or placebo (P)) on spontaneous nasal and induced bronchial
symptoms at days 29–30
Time (min) Mean score SD Minimum score Maximum score
5 7.5 0.53 7 8
Dosing 6.9 0.74 6 8
1 6.9 0.67 6 8
2 6.9 0.75 6 8
5 4.3 1.26 2 6
8 2.1 0.57 1 3
10 2.0 0.82 1 3
15 2.0 0.63 1 3
20 1.8 0.67 1 3
25 1.8 0.79 1 3
30 1.7 0.63 1 3
45 1.8 1.03 1 3
60 1.6 1.00 1 3
Table 4. Open label induced cough challenge with broccoli (number of challenges: 10)
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http://doi.org/10.1016/j.waojou.2020.100498In the broccoli group, induced cough score was
around 7–8 before the dose and below 3 after 6–
9 min (Fig. 5). Score levels remained at between
0 and 3 for the 60-min duration of the test. In the
placebo group, there was merely no effect. The
results for both the active and placebo groups
were very consistent. The results for the active
group were consistent with the open cough chal-
lenges (Table 3).In the broccoli group, 6, 6, 10, and 10 episodes
of spontaneous cough were recorded for over
60 min, compared to 21, 25, 26, and 28 in the
placebo group.
In the broccoli group, nasal symptoms were
reduced very rapidly (2–3 min), except for BG3.
Nasal obstruction was the only symptom recorded
during the baseline of BG1, BG2, and BG4,
Volume 14, No. 1, January 2021 11whereas both nasal obstruction and rhinorrhea
(VAS: 3) were recorded during BG3 baseline. The
patient needed to blow his nose at 7 min (VAS 7).
After 12–15 min, symptoms increased. In the pla-
cebo group, symptoms were variable but were
never below 2, and all 3 tests required nose
blowing (indicated as VAS 7).
VAS spontaneous cough 5 was noted at 4h30,
5h00, 6h00 and 7h45 after the ingestion of the
broccoli capsules, whereas it was present at 60 min
(two cases), 1h15 and 1h30 after the ingestion of
the placebo capsules.DISCUSSION
These 3 experimental clinical cases, like any
clinical case, should be considered carefully in
terms of efficacy, and with caution in terms of
safety. Moreover, in the first case, the patient and
the investigator who proposed the treatment were
the same person. The case has been well
described and the study analyzed — as if it were to
be published — right from the onset of symptoms
and the first dose of the fast-acting broccoli cap-
sules (day 3). Safety should be considered carefully
as high doses are required.
Several foods act on Nrf2.4,25–31 It has been
proposed but not confirmed that Nrf2-interacting
nutrients may be effective in COVID 19.32-36 The
cases presented herein are a proof-of-concept for
the clinical effects of Nrf2-interacting nutrients in
patients with COVID-19 using broccoli and glu-
coraphanin. We have proposed that differences in
death rates between and within countries are
associated with Nrf2-interacting nutrients.1–3 In the
present study, there are 6 levels of evidence
suggesting that broccoli components are
effective in COVID-19: (i) During COVID-19, with
initial symptoms (days 3 and 4) and the cytokine
storm (days 7–12), a high dose of broccoli was al-
ways effective within minutes; (ii) When the broc-
coli was stopped, the same COVID-19 symptoms
reappeared and were controlled with the same
speed using the same treatment; (iii) Broccoli
appeared to be effective within minutes on most of
the COVID-19 symptoms except fever. However,
for clinical case 2, smell and taste were reduced
but specific tests would have been required for full
appraisal;37 (iv) The effect of broccoli was also
found in clinical case 1 during the recoveryperiod after the cytokine storm; (v) A double-
blind, placebo-controlled induced cough chal-
lenge was performed on days 28 and 29. The re-
sults were perfectly in line with 17 open induced
cough challenges and with the clinical benefits
observed on days 3, 4, 7, 8 (broccoli capsules only)
and on days 9, 10, 11, 12 (broccoli capsules and
paracetamol);
The label indicates that there is 10% of glucor-
aphanin in the broccoli capsules. However, the
exact dosage could not be found, neither on the
label nor on the website of the manufacturer. The
capsule has therefore been analyzed and the
doses of glucoraphanin are lower than those
indicated on the label (3% instead of 10%). Glu-
coraphanin is an important component of broccoli
because sulforaphane [1-isothiocyanato-4-(meth-
ylsulfinyl) butane], found in a stored form such as
glucoraphanin in cruciferous vegetables, is the
most potent natural activator of Nrf2.38 Present in
the plant as its precursor, glucoraphanin,
sulforaphane is formed through the action of
myrosinase, a b-thioglucosidase present in either
the plant tissue or the mammalian gut
microbiome.4,5 Sulforaphane is a clinically
relevant nutraceutical compound used for the
prevention and treatment of chronic diseases and
may be involved in ageing.39 However, the very
early effects of broccoli cannot be attributed to
sulforaphane.
The mechanisms of action of broccoli are un-
clear. The immediate effect on cough in COVID-19
was noted at 5–10 min after ingestion in both
clinical cases. It is interesting to note that most
COVID-19 symptoms are rapidly improved under
broccoli, except cough which is either less well
controlled or at a different kinetic (starts early and
takes 2–3 h to be improved but not fully
controlled). The speed of onset of broccoli is sur-
prising but highly consistent (4 DB-PC induced
cough challenges and 10 open label challenges),
and it is possible that changes in oxidative stress
can be very rapid. Nasal effects are even faster.
Sulforaphane improves respiratory function for
people with lung problems by increasing state 3
respiration and respiration linked to ATP synthesis
in mitochondria.40–43 As such, it also promotes
glucose and lipid utilization. Thus, in particular,
hypoxia-induced injuries are prevented.
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46 whereas sulforaphane from broccoli has a
bronchoprotective response through Nrf2 47 and
reduces nasal response to diesel exhaust
particulates.26 Sulforaphane has an antibiotic
function48 and antiviral functions,49 as well as
antiproliferative activities that lead to its use as a
chemopreventive agent.50,51 Oxidant activation
of the airway neurons induces respiratory
depression, nasal obstruction, sneezing, and
cough.52,53
However, other mechanisms may also be pro-
posed. The cough reflex is regulated by vagal,
sensory afferent nerves which innervate the
airway. The transient receptor potential (TRP)
family of ion channels is expressed on sensory
nerve terminals, and, when activated, can evoke
cough.54 Diesel exhaust can act on airway
sensory neurons.55 TRPA1 (Transient Receptor
Potential Ankyrin type 1), a member of the TRP
gene family, is a major oxidant sensor in airway
sensory neurons.56,57 It is possible that the early
effects on the nose may be mediated through
these mechanisms through a TRPA1 reflex.
Another mechanism may be proposed. The
TRPA1 channel may be activated and
desensitized at high doses within seconds by
electrophilic pungent compounds.58 Broccoli
contains flavonoids 59,60 including quercetin,59
naringenin, 61 and kaempferol 62 that interact
with TRPA1 and TRPV1 (Transient Receptor
Potential Vanillin type 1). We suggest that
electrophilic ligands activate and desensitize
TRPA1 and that they also activate Nrf2, thus
blocking the activation of TRPA1 by reactive
oxygen species (ROS) produced by COVID-19.
Paracetamol (acetaminophen) has TRPA1-
independent antipyretic effects 63 and TRPA1-
dependent effects on pain.64 The electrophilic
metabolites N-acetyl-p-benzoquinone imine
(NAPQI, hepatotoxic metabolite) and p-
benzoquinone, but not paracetamol itself,
activate TRPA1.65 They also activate and sensitize
TRPV1 (transient receptor potential vanillin 1) by
interacting with intracellular cysteines.66,67
NAPQI also directly activates Nrf2,68 and
benzoquinone desensitizes TRPA1.69 TRPA1, an
excitatory ion channel originally associated with
the receptor of mustard oil in sensory neurons,70
plays a pivotal role in detecting cysteine-reactiveirritants and in augmenting sensory or vagal
nerve discharges to evoke several COVID-19
symptoms including cough.54,71,72 TRPV1, also
known as the capsaicin receptor73, is also
involved in cough and lung injury. TRPA1 and
TRPV1 are probably desensitized and have a
cross-talk with Nrf2 (Bousquet et al, paper sub-
mitted, available online).74
Medications in capsules can be active after 1–
2 min and pass into the blood stream within 2 min.
The effects on cough are probably more complex.
The early effects of the ingestion of the broccoli
capsules can only be ascribed to broccoli, since
sulforaphane cannot be produced so fast. The
rapid but steady decrease in cough symptoms may
be associated with the same mechanisms, but
probably include other mechanisms. It is unlikely
that cough in COVID-19 is associated mainly to
eosinophilic inflammation, since inhaled cortico-
steroids appeared to be ineffective in the first
clinical case.
One question that cannot be answered is
whether broccoli reduced the severity of the
cytokine storm. The patient of the first clinical case
was at high risk of developing severe symptoms
during the cytokine storm due to the number of
symptoms he experienced during the first phase of
COVID-19 as well as his age and sex. Moreover, he
developed an early cytokine storm on day 6 that
was long lasting. However, symptoms were
controlled by the treatment and he never suffered
from dyspnea or from a respiratory rate of above
24. He had a mild inflammatory response and the
CT-scan showed few COVID-19 typical lesions. It
may be suggested that broccoli prevented a se-
vere COVID-19 illness. The second clinical case
was carried out during the cytokine storm and
symptoms were improved by a lower dose of
broccoli.
Using the dose of broccoli recommended by
the manufacturer, there was no preventive effect
on SARS-CoV-2. However, it is likely that the dose
was insufficient for any such effect. The doses
required for effective action during the COVID-19
symptoms of case 1 were quite high and should
raise safety concerns. We used a daily dose of
under 200 mmol of glucoraphanin, and trials with
doses of up to 800 mmol daily have been reported
without safety concerns.9,25,75 However, such a
Volume 14, No. 1, January 2021 13high dose may have pharmacologic effects such as
the antagonism of aryl hydrocarbon receptors
modulating the CYP1 (Cytochrome P450, family
1, subfamily A, polypeptide 1) family of
cytochromes P450 76 or a direct effect of
CYP1.77 These effects must be studied carefully
before any trial is carried out. Moreover, in
broccoli seeds, there are many other compounds
that may have pharmacologic properties when
ingested at high doses.25 Thus, this experimental
clinical case is a proof-of-concept to confirm the
hypothesis but cannot be used in practice before
more safety data are available. Another safety
issue is the reduction of the cough that may have
been helpful in expelling pathogens. This would
be of interest in the first week of COVID-19 as the
cytokine storm and the recovery phase progress
without infection.
The patient of the first clinical case is allergic to
grass pollen and cat and also suffers from mild
intermittent asthma. It might be possible that some
of the effects of the Nrf2-interacting nutrients are
related to bronchial hyperreactivity, but inhalation
of formoterol-budesonide low dose did not
reduce cough. However, it cannot be ruled out that
the results observed on cough may be partly
associated with asthma or allergy. The patient also
attempted to reduce nasal symptoms with
azelastine-fluticasone propionate but there was no
effect. Moreover, nasal symptoms are mainly
characterized by nasal obstruction alone that is not
associated with allergic triggers.
These 3 clinical cases should be considered with
care and confirmed by proper trials on efficacy and
safety. However, they are in keeping with the hy-
pothesis that cabbage may reduce COVID-19 1-3
and with many papers highlighting the role of
nutrition in COVID-19. What is novel is the
demonstration in all 3 clinical cases that the hy-
pothesis is supported and that the speed of action
of the nutrients is so fast. Research is needed to (i)
confirm the case, (ii) investigate in which patients
the treatment is safe and effective, (iii) differentiate
the effects on Nrf2 and TRPA1, (iv) assess the
different broccoli compounds that are active (early
and late), (v) assess the dose required for effective
action, (vi) confirm the speed of onset of action,
and (vii) optimize the nutrients to be administered
(as nutrients or active molecules).Abbreviations
ACE: Angiotensin converting enzyme; AT1R: Angiotensin II
receptor type 1; BMI: Body mass index; Broccoli: Broccoli
seed capsules; COVID-19: Coronavirus 19 disease; NAPQI:
N-acetyl-p-benzoquinone imine; Nrf2: Nuclear factor
(erythroid-derived 2)-like 2; SARS: Severe acute respiratory
syndrome; SARS-Cov-2: Severe acute respiratory syndrome
coronavirus 2; TRP: Transient receptor potential; TRPA1:
Transient receptor potential ankyrin 1; TRPV1: Transient
receptor potential vanillin 1; VAS: Visual analogue scale
Funding
None.
Availability of data and materials
Not applicable.
Authors' contributions
JB proposed the treatment and was the patient. He
discussed it with JMA, WC and TZ. JB wrote the paper.
VLM, HB and JR were the physicians of JB. AB, JPC, AAC,
AF, TH, GI, LK, PK, EM, JM, BS and AV were the ARIA
reviewers. RdlT and NPL discussed the broccoli content. All
authors were requested to comment on the concept and to
review the paper.
Ethics approval and consent to participate
Not applicable since this was a food supplement used at
regular doses by the patients of cases 2 and 3 and at higher
doses (case 1) by the author of the study.
Consent for publication
All authors gave their informed consent to publish the
work.
Declaration of competing interest
None of the authors declared any competing interest.
Acknowledgements
Prof. Bernard Bataille (Pharmacy school of Montpellier)
who gave advice for the absorption of drugs in capsules,
the Pharmacie du Plan des Quatre Seigneurs (Montpellier)
who prepared the placebo capsules for the cough
challenge, and Ms Anna Bedbrook who reviewed the
English.
Author details
aCharité, Universitätsmedizin Berlin, Humboldt-Universität
zu Berlin, and Berlin Institute of Health, Comprehensive
Allergy Center, Department of Dermatology and Allergy,
Berlin, Germany. bMACVIA France, University Hospital,
Montpellier, France. cMaladies Infectiouses et Tropicales,
CHU Montpellier, France. dDepartment of Geriatrics,
Montpellier University Hospital, Montpellier, France.
eMedical Consulting Czarlewski, Levallois, France. fMASK-
air, Montpellier, France. gLaboratoire de Biochimie et
Hormonologie, PhyMedExp, Université de Montpellier,
14 Bousquet et al. World Allergy Organization Journal (2021) 14:100498
http://doi.org/10.1016/j.waojou.2020.100498INSERM, CNRS, CHU de Montpellier, France. hCIBER
Fisiopatologia de La Obesidad y Nutrición (CIBEROBN),
Madrid, Spain. iIMIM (Hospital del Mar Research Institute),
Barcelona, Spain. jUniversitat Pompeu Fabra (UPF),
Barcelona, Spain. kCIBER Epidemiología y Salud Pública
(CIBERESP), Barcelona, Spain. lISGlobal. ISGlobAL,
Barcelona, Centre for Research in Environmental
Epidemiology (CREAL), Barcelona, Spain. mFundação
ProAR, Federal University of Bahia and GARD/WHO
Planning Group, Salvador, Brazil. nDivision of Allergy,
Department of Pediatric Medicine - The Bambino Gesù
Children's Research Hospital Holy see, Rome, Italy. oSkin
and Allergy Hospital, Helsinki University Hospital, And
University of Helsinki, Helsinki, Finland. pDepartment of
Advanced Biomedical Sciences, Federico II University,
Napoli, Italy. qCenter for Rhinology and Allergology,
Wiesbaden, Germany. rDivision of Internal Medicine,
Asthma and Allergy, Barlicki University Hospital, Medical
University of Lodz, Poland. sInstitute of Environmental
Medicine, Karolinska Institutet and Sachs' Children's
Hospital, Stockholm, Sweden. tRhinology Unit & Smell
Clinic, ENT Department, Hospital Clinic - Clinical &
Experimental Respiratory Immunoallergy, IDIBAPS,
CIBERES, Universitat de Barcelona, Barcelona, Spain.
uDepartment of Prevention of Environmental Hazards and
Allergology, Medical University of Warsaw, Poland. vVilnius
University Faculty of Medicine, Institute of Clinical Medicine
& Institute of Health Sciences, Vilnius, Lithuania.REFERENCES
1. Bousquet J, Czarlewski W, Blain H, Zuberbier T, Anto J. Rapid
Response: why Germany's case fatality rate seems so low: is
nutrition another possibility. Bmj; 2020. https://www.bmj.com/
content/369/bmj.m1395/rr-12.
2. Bousquet J, Anto JM, Iaccarino G, et al. Is diet partly
responsible for differences in COVID-19 death rates between
and within countries? Clin Transl Allergy. 2020;10:16.
3. Bousquet J, Anto JM, Czarlewski W, et al. Cabbage and
fermented vegetables: from death rate heterogeneity in
countries to candidates for mitigation strategies of severe
COVID-19. Allergy. Aug 6 2020. https://doi.org/10.1111/all.
14549. Online ahead of print.
4. Yagishita Y, Fahey JW, Dinkova-Kostova AT, Kensler TW.
Broccoli or sulforaphane: is it the source or dose that matters?
Molecules. 2019;24.
5. Hindson J. Brassica vegetable metabolism by gut microbiota.
Nat Rev Gastroenterol Hepatol. 2020;17:195.
6. Chen X, Jiang Z, Zhou C, et al. Activation of Nrf2 by
sulforaphane inhibits high glucose-induced progression of
pancreatic cancer via AMPK dependent signaling. Cell Physiol
Biochem. 2018;50:1201–1215.
7. Kubo E, Chhunchha B, Singh P, Sasaki H, Singh DP.
Sulforaphane reactivates cellular antioxidant defense by
inducing Nrf2/ARE/Prdx6 activity during aging and oxidative
stress. Sci Rep. 2017;7:14130.8. Xin Y, Bai Y, Jiang X, et al. Sulforaphane prevents angiotensin
II-induced cardiomyopathy by activation of Nrf2 via
stimulating the Akt/GSK-3ss/Fyn pathway. Redox Biol.
2018;15:405–417.
9. Yang L, Palliyaguru DL, Kensler TW. Frugal chemoprevention:
targeting Nrf2 with foods rich in sulforaphane. Semin Oncol.
2016;43:146–153.
10. Zhou S, Wang J, Yin X, et al. Nrf2 expression and function, but
not MT expression, is indispensable for sulforaphane-
mediated protection against intermittent hypoxia-induced
cardiomyopathy in mice. Redox Biol. 2018;19:11–21.
11. Fahey JW, Wade KL, Stephenson KK, et al. Bioavailability of
sulforaphane following ingestion of glucoraphanin-rich
broccoli sprout and seed extracts with active myrosinase: a
pilot study of the effects of proton pump inhibitor
administration. Nutrients. 2019;11.
12. Martinez-Huelamo M, Rodriguez-Morato J, Boronat A, de la
Torre R. Modulation of Nrf2 by olive oil and wine polyphenols
and neuroprotection. Antioxidants (Basel). 2017:6.
13. Martucci M, Ostan R, Biondi F, et al. Mediterranean diet and
inflammaging within the hormesis paradigm. Nutr Rev.
2017;75:442–455.
14. Abedi V, Olulana O, Avula V, et al. Racial, Economic and Health
Inequality and COVID-19 Infection in the United States.
medRxiv. 2020.
15. Van Belle S, Affun-Adegbulu C, Soors W, et al. COVID-19 and
informal settlements: an urgent call to rethink urban
governance. Int J Equity Health. 2020;19:81.
16. Pereira RJ, Nascimento G, Gratao LHA, Pimenta RS. The risk of
COVID-19 transmission in favelas and slums in Brazil. Publ
Health. 2020;183:42–43.
17. Bousquet J, Czarlewski W, Zuberbier T, et al. Potential control
of COVID-19 symptoms by Nrf2-interacting nutrients with
TRPA1 (transient receptor potential ankyrin 1) agonist activity.
Clin Transl Allergy; 2020. Article number: 58 http://www.
ga2len.net.in.press.
18. Bousquet J, Bedbrook A, Czarlewski W, et al. Guidance to 2018
good practice: ARIA digitally-enabled, integrated, person-
centredcare for rhinitisandasthma.ClinTranslAllergy. 2019;9:16.
19. BlainH, RollandY,TuaillonE, et al. Efficacyof a test-retest strategy
in residents andhealth carepersonnel of a nursing home facing a
COVID-19 outbreak. J Am Med Dir Assoc. 2020;21:933–936.
20. Bousquet PJ, Combescure C, Neukirch F, et al. Visual analog
scales can assess the severity of rhinitis graded according to
ARIA guidelines. Allergy. 2007;62:367–372.
21. Caimmi D, Baiz N, Tanno LK, et al. Validation of the MASK-
rhinitis visual analogue scale on smartphone screens to assess
allergic rhinitis control. Clin Exp Allergy. 2017;47:1526–1533.
22. Klimek L, Bergmann KC, Biedermann T, et al. Visual analogue
scales (VAS): measuring instruments for the documentation of
symptoms and therapy monitoring in cases of allergic rhinitis
in everyday health care: position paper of the German society
of allergology (AeDA) and the German society of allergy and
clinical immunology (DGAKI), ENT section, in collaboration
with the working group on clinical immunology, allergology
and environmental medicine of the German society of
Volume 14, No. 1, January 2021 15otorhinolaryngology, head and neck surgery (DGHNOKHC).
Allergo J Int. 2017;26:16–24.
23. Spinou A, Birring SS. An update on measurement and
monitoring of cough: what are the important study endpoints?
J Thorac Dis. 2014;6:S728–S734.
24. Wang Z, Wang M, Wen S, Yu L, Xu X. Types and applications of
cough-related questionnaires. J Thorac Dis. 2019;11:4379–
4388.
25. Chartoumpekis DV, Ziros PG, Chen JG, Groopman JD,
Kensler TW, Sykiotis GP. Broccoli sprout beverage is safe for
thyroid hormonal and autoimmune status: results of a 12-week
randomized trial. Food Chem Toxicol. 2019;126:1–6.
26. Heber D, Li Z, Garcia-Lloret M, et al. Sulforaphane-rich broccoli
sprout extract attenuates nasal allergic response to diesel
exhaust particles. Food Funct. 2014;5:35–41.
27. Xu L, Nagata N, Ota T. Glucoraphanin: a broccoli sprout
extract that ameliorates obesity-induced inflammation and
insulin resistance. Adipocyte. 2018;7:218–225.
28. Bonnefont-Rousselot D. Resveratrol and cardiovascular
diseases. Nutrients. 2016;8.
29. Ashrafizadeh M, Fekri HS, Ahmadi Z, Farkhondeh T,
Samarghandian S. Therapeutic and biological activities of
berberine: the involvement of Nrf2 signaling pathway. J Cell
Biochem. 2020;121:1575–1585.
30. Xu Z, Feng W, Shen Q, et al. Rhizoma coptidis and berberine
as a natural drug to combat aging and aging-related diseases
via anti-oxidation and AMPK activation. Aging Dis. 2017;8:
760–777.
31. Yan Z, Zhong Y, Duan Y, Chen Q, Li F. Antioxidant mechanism
of tea polyphenols and its impact on health benefits. Anim
Nutr. 2020;6:115–123.
32. Cuadrado A, Pajares M, Benito C, et al. Can activation of NRF2
Be a strategy against COVID-19? Trends Pharmacol Sci.
2020;41(9):598–610. https://doi.org/10.1016/j.tips.2020.07.003.
33. Hassan SM, Jawad MJ, Ahjel SW, et al. The Nrf2 activator
(DMF) and covid-19: is there a possible role? Med Arch.
2020;74:134–138.
34. Horowitz RI, Freeman PR. Three novel prevention, diagnostic,
and treatment options for COVID-19 urgently necessitating
controlled randomized trials. Med Hypotheses. 2020;143:
109851.
35. Martinez-Sanchez G, Schwartz A, Donna VD. Potential
cytoprotective activity of ozone therapy in SARS-CoV-2/
COVID-19. Antioxidants (Basel). 2020;9.
36. McCord JM, Hybertson BM, Cota-Gomez A, Gao B. Nrf2
Activator PB125(R) as a Potential Therapeutic Agent Against
COVID-19. bioRxiv. 2020.
37. Rojas-Lechuga MJ, Izquierdo-Dominguez A, Chiesa-
Estomba C, et al. Chemosensory dysfunction in COVID-19 out-
patients. Eur Arch Oto-Rhino-Laryngol. 2020;25:1–8. https://
doi.org/10.1007/s00405-020-06266-3.
38. Bai Y, Wang X, Zhao S, Ma C, Cui J, Zheng Y. Sulforaphane
protects against cardiovascular disease via Nrf2 activation.
Oxid Med Cell Longev. 2015;2015:407580.
39. Houghton CA. Sulforaphane: its "coming of age" as a clinically
relevant nutraceutical in the prevention and treatment of
chronic disease. Oxid Med Cell Longev. 2019;2019:2716870.40. Carrasco-Pozo C, Tan KN, Borges K. Sulforaphane is
anticonvulsant and improves mitochondrial function.
J Neurochem. 2015;135:932–942.
41. Langston-Cox A, Muccini AM, Marshall SA, et al. Sulforaphane
improves syncytiotrophoblast mitochondrial function after
in vitro hypoxic and superoxide injury. Placenta. 2020;96:44–
54.
42. Lemarie A, Grimm S. Mitochondrial respiratory chain
complexes: apoptosis sensors mutated in cancer? Oncogene.
2011;30:3985–4003.
43. Sun Z, Niu Z, Wu S, Shan S. Protective mechanism of
sulforaphane in Nrf2 and anti-lung injury in ARDS rabbits. Exp
Ther Med. 2018;15:4911–4915.
44. Sudini K, Diette GB, Breysse PN, et al. A randomized
controlled trial of the effect of broccoli sprouts on antioxidant
gene expression and airway inflammation in asthmatics.
J Allergy Clin Immunol Pract. 2016;4:932–940.
45. Wise RA, Holbrook JT, Criner G, et al. Lack of effect of oral
sulforaphane administration on Nrf2 expression in copd: a
randomized, double-blind, placebo controlled trial. PLoS One.
2016;11, e0163716.
46. Duran CG, Burbank AJ, Mills KH, et al. A proof-of-concept
clinical study examining the NRF2 activator sulforaphane
against neutrophilic airway inflammation. Respir Res.
2016;17:89.
47. Fahey JW, Holtzclaw WD, Wehage SL, Wade KL,
Stephenson KK, Talalay P. Sulforaphane bioavailability from
glucoraphanin-rich broccoli: control by active endogenous
myrosinase. PLoS One. 2015;10, e0140963.
48. Fahey JW, Haristoy X, Dolan PM, et al. Sulforaphane inhibits
extracellular, intracellular, and antibiotic-resistant strains of
Helicobacter pylori and prevents benzo[a]pyrene-induced
stomach tumors. Proc Natl Acad Sci U S A. 2002;99:7610–
7615.
49. Muller L, Meyer M, Bauer RN, et al. Effect of broccoli sprouts
and live attenuated influenza virus on peripheral blood natural
killer cells: a randomized, double-blind study. PLoS One.
2016;11, e0147742.
50. Negrette-Guzman M, Huerta-Yepez S, Tapia E, Pedraza-
Chaverri J. Modulation of mitochondrial functions by the
indirect antioxidant sulforaphane: a seemingly contradictory
dual role and an integrative hypothesis. Free Radic Biol Med.
2013;65:1078–1089.
51. Alumkal JJ, Slottke R, Schwartzman J, et al. A phase II study of
sulforaphane-rich broccoli sprout extracts in men with
recurrent prostate cancer. Invest N Drugs. 2015;33:480–489.
52. Pryor WA, Stone K. Oxidants in cigarette smoke. Radicals,
hydrogen peroxide, peroxynitrite, and peroxynitrite. Ann N Y
Acad Sci. 1993;686:12–27. discussion -8.
53. Andre E, Campi B, Materazzi S, et al. Cigarette smoke-induced
neurogenic inflammation is mediated by alpha,beta-
unsaturated aldehydes and the TRPA1 receptor in rodents.
J Clin Invest. 2008;118:2574–2582.
54. Bonvini SJ, Belvisi MG. Cough and airway disease: the role of
ion channels. Pulm Pharmacol Therapeut. 2017;47:21–28.
55. Robinson RK, Birrell MA, Adcock JJ, et al. Mechanistic link
between diesel exhaust particles and respiratory reflexes.
J Allergy Clin Immunol. 2018;141:1074–10784 e9.
16 Bousquet et al. World Allergy Organization Journal (2021) 14:100498
http://doi.org/10.1016/j.waojou.2020.10049856. Bessac BF, Sivula M, von Hehn CA, Escalera J, Cohn L,
Jordt SE. TRPA1 is a major oxidant sensor in murine airway
sensory neurons. J Clin Invest. 2008;118:1899–1910.
57. Yamamoto S, Shimizu S. Significance of TRP channels in
oxidative stress. Eur J Pharmacol. 2016;793:109–111.
58. Kistner K, Siklosi N, Babes A, et al. Systemic desensitization
throughTRPA1channelsbycapsazepineandmustardoil - anovel
strategy against inflammation and pain. Sci Rep. 2016;6:28621.
59. Nakamura T, Miyoshi N, Ishii T, Nishikawa M, Ikushiro S,
Watanabe T. Activation of transient receptor potential ankyrin
1 by quercetin and its analogs. Biosci Biotechnol Biochem.
2016;80:949–954.
60. Mageney V, Neugart S, Albach DC. A guide to the variability of
flavonoids in Brassica oleracea. Molecules. 2017;22.
61. Park M, Kim K, Lee YM, Rhyu MR, Kim HY. Naringenin
stimulates cholecystokinin secretion in STC-1 cells. Nutr Res
Pract. 2014;8:146–150.
62. do Nascimento JET, de Morais SM, de Lisboa DS, et al. The
orofacial antinociceptive effect of Kaempferol-3-O-rutinoside,
isolated from the plant Ouratea fieldingiana, on adult
zebrafish (Danio rerio). Biomed Pharmacother. 2018;107:
1030–1036.
63. Mirrasekhian E, Nilsson JLA, Shionoya K, et al. The antipyretic
effect of paracetamol occurs independent of transient
receptor potential ankyrin 1-mediated hypothermia and is
associated with prostaglandin inhibition in the brain. Faseb J.
2018;32:5751–5759.
64. Fresno N, Perez-Fernandez R, Goicoechea C, et al. Adamantyl
analogues of paracetamol as potent analgesic drugs via
inhibition of TRPA1. PLoS One. 2014;9, e113841.
65. Andersson DA, Gentry C, Moss S, Bevan S. Transient receptor
potential A1 is a sensory receptor for multiple products of
oxidative stress. J Neurosci. 2008;28:2485–2494.
66. Eberhardt MJ, Schillers F, Eberhardt EM, et al. Reactive
metabolites of acetaminophen activate and sensitize the
capsaicin receptor TRPV1. Sci Rep. 2017;7:12775.67. Wang Y, Lin W, Wu N, et al. An insight into paracetamol and its
metabolites using molecular docking and molecular dynamics
simulation. J Mol Model. 2018;24:243.
68. Copple IM, Goldring CE, Jenkins RE, et al. The hepatotoxic
metabolite of acetaminophen directly activates the Keap1-Nrf2
cell defense system. Hepatology. 2008;48:1292–1301.
69. Ibarra Y, Blair NT. Benzoquinone reveals a cysteine-dependent
desensitization mechanism of TRPA1. Mol Pharmacol.
2013;83:1120–1132.
70. Jordt SE, Bautista DM, Chuang HH, et al. Mustard oils and
cannabinoids excite sensory nerve fibres through the TRP
channel ANKTM1. Nature. 2004;427:260–265.
71. Millqvist E. TRPV1 and TRPM8 in treatment of chronic cough.
Pharmaceuticals (Basel). 2016;9.
72. Taylor-Clark TE. Role of reactive oxygen species and TRP
channels in the cough reflex. Cell Calcium. 2016;60:155–162.
73. Zheng W, Wen H. Heat activation mechanism of TRPV1: new
insights from molecular dynamics simulation. Temperature
(Austin). 2019;6:120–131.
74. Bousquet J, Czarlewski W, Zuberbier T, de-la-Torre R, Anto J.
Induced cough challenges in a single patient with COVID-19
showing an interplay between Nrf2, TRPA1 and TRPV1
agonists 2020;https://www.ga2len.net.
75. Leone A, Diorio G, Sexton W, et al. Sulforaphane for the
chemoprevention of bladder cancer: molecular mechanism
targeted approach. Oncotarget. 2017;8:35412–35424.
76. Abdull Razis AF, Noor NM. Naturally-occurring glucosinolates,
glucoraphanin and glucoerucin, are antagonists to aryl
hydrocarbon receptor as their chemopreventive potency.
Asian Pac J Cancer Prev APJCP. 2015;16:5801–5805.
77. Furue M, Uchi H, Mitoma C, et al. Antioxidants for healthy skin:
the emerging role of aryl hydrocarbon receptors and nuclear
factor-erythroid 2-related factor-2. Nutrients. 2017;9.
